Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting (NCT06991348)

Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting NCT06991348 Sponsor: Carnot Laboratories Condition: Gastro-oesophageal Reflux Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06991348 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Gord

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with acid reflux disease (GERD) or a related condition (NERD) through a camera examination of the stomach, done within the last 15 days.
People who have had a specific test measuring acid and fluid movement in the food pipe (called impedance pHmetry) with results confirming reflux, done within the last 15 days.
People who have been experiencing recurring symptoms of heartburn and regurgitation (stomach contents coming back up) for at least 3 months.

Who may not be able to join:

People who are known to have an allergic reaction or sensitivity to the study medications tegoprazan or pantoprazole, or any of their ingredients.
People who are currently taking any of the following medications: atazanavir, nelfinavir, or rilpivirine.
People who have kidney disease or liver disease, including non-alcoholic hepatitis.
People who have bleeding in the upper part of their digestive tract (stomach or food pipe).
People who have had a stomach or small intestine ulcer within the 2 months before the screening visit.
People who have previously had surgery on their stomach or food pipe.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06991348

Sponsor: Carnot Laboratories

Phase: Phase 4

Status: Recruiting

Condition: Gastro-oesophageal Reflux Disease

More information: https://clinicaltrials.gov/study/NCT06991348

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with acid reflux disease (GERD) or a related condition (NERD) through a camera examination of the stomach, done within the last 15 days.
People who have had a specific test measuring acid and fluid movement in the food pipe (called impedance pHmetry) with results confirming reflux, done within the last 15 days.
People who have been experiencing recurring symptoms of heartburn and regurgitation (stomach contents coming back up) for at least 3 months.

Who may not be able to join:

People who are known to have an allergic reaction or sensitivity to the study medications tegoprazan or pantoprazole, or any of their ingredients.
People who are currently taking any of the following medications: atazanavir, nelfinavir, or rilpivirine.
People who have kidney disease or liver disease, including non-alcoholic hepatitis.
People who have bleeding in the upper part of their digestive tract (stomach or food pipe).
People who have had a stomach or small intestine ulcer within the 2 months before the screening visit.
People who have previously had surgery on their stomach or food pipe.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 4

Sponsor

Carnot Laboratories

Registry

ClinicalTrials.gov

Start date

30 July 2024

Est. completion

30 November 2025

Where this trial is recruiting

🇲🇽 Mexico

Primary endpoints

Proportion of subjects with resolution of the main symptoms of gastroesophageal reflux disease

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov